{"data":{"responsecode":"000","responsemsg":"","quote":{"hi":"29.460","rs_stock_flag":false,"fiscal_year_end":"2024年12月31日","hist_closedate":"2025年9月25日","replication_method":null,"amt_os":"227,071,600","primaryexch":"香港交易所","ric":"2509.HK","product_subtype":null,"db_updatetime":"2025年9月28日08:06","mkt_cap_u":"B","am_u":"M","ew_sub_right":"","secondary_listing":false,"ew_amt_os_cur":null,"ccy":"HKD","management_fee":"","ew_underlying_code":null,"trdstatus":"N","nav":"","original_offer_price":"","issue":"","asset_class":null,"eps":0.0,"inline_upper_strike_price":"","sedol":"BSKTTC7","am":"14.61","iv":"","ew_strike":"","as":"29.400","geographic_focus":null,"incorpin":"中華人民共和國","etp_baseCur":null,"ew_amt_os":"","bd":"29.100","registrar":"卓佳證券登記有限公司","depositary":null,"exotic_type":null,"callput_indicator":null,"primary_market":null,"underlying_index":null,"lot":"200","update_time":"2025-09-28 00:06:03.0","lo52":"5.950","shares_issued_date":"2025年8月31日","premium":"","strike_price_ccy":null,"yield":"","vo_u":"K","base_currency":null,"coupon":"","expiry_date":"","chairman":"裘霽宛","underlying_ric":"2509.HK","hi52":"34.340","issuer_name":"江蘇荃信生物醫藥股份有限公司 - B - H股","h_share_flag":false,"ew_sub_per_from":"","div_yield":"","interest_payment_date":"-","updatetime":"2025年9月26日16:08","aum_date":"","lo":"27.700","mkt_cap":"6.67","f_aum_hkd":null,"ew_sub_per_to":"","ls":"29.400","nav_date":"","csic_classification":null,"floating_flag":false,"issued_shares_note":null,"nom_ccy":null,"eff_gear":"","board_lot_nominal":null,"hsic_ind_classification":"醫療保健業 - 藥品及生物科技","ew_desc":null,"inception_date":"","nc":"+0.160","aum":"","issued_shares_class_B":null,"vo":"512.20","secondary_listing_flag":false,"listing_date":"2024年3月20日","issued_shares_class_A":null,"as_at_label":"截至","ew_amt_os_dat":"","nm":"江蘇荃信生物醫藥股份有限公司 - B - H股","nm_s":"荃信生物－Ｂ","sym":"2509","inline_lower_strike_price":"","listing_category":"主要上市","ew_strike_cur":null,"exotic_warrant_indicator":null,"investment_focus":null,"call_price":"","tck":"0.020","strike_price":"","summary":"江蘇荃信生物醫藥股份有限公司是一家主要從事生物製藥的中國公司。該公司主要從事自體免疫及過敏性疾病生物療法的生物科技研發。該公司業務主要涵蓋四大疾病領域，包括皮膚、風濕、呼吸道及消化道疾病。該公司正在研發的項目有8個，目標適應症包括乾癬、異位性皮膚炎、類風濕性關節炎、發炎性腸道疾病、氣喘等。該公司核心產品有QX002N和QX005N。","op":"29.220","aum_u":"","nav_ccy":null,"class_B_description":null,"os":"","wnt_gear":"","transfer_of_listing_date":"","hsic_sub_sector_classification":"生物技術","amt_ccy":null,"class_A_description":null,"domicile_country":null,"entitlement_ratio":"","product_type":"EQTY","office_address":"中國<br/>江蘇省泰州市<br/>藥城大道907號<br/>1號樓1310室","pc":"+0.55","days_to_expiry":null,"underlying_code":null,"pe":"","eps_ccy":"RMB","hdr":false,"launch_date":"","hc":"29.240","isin":"CNE1000069W9","moneyness":""}},"qid":"1759074351739"}
